Emerging Therapies Reshape the Open-Angle Glaucoma Treatment Market Outlook
Author : John snow | Published On : 07 Oct 2026
The open-angle glaucoma market is positioned for steady expansion as the global burden of glaucoma continues to rise, particularly among aging populations. Greater awareness of eye health, improved screening, earlier diagnosis, and advances in treatment are expected to support market growth. At the same time, the anticipated introduction of emerging therapies such as Citicolinem, PA5108, AGN-193408 SR, PER-001, AMDX-2011P, and other pipeline candidates could significantly influence future treatment strategies and competitive dynamics.
DelveInsight's Open-Angle Glaucoma Market Insights report provides a comprehensive assessment of current treatment practices, emerging therapies, individual drug market shares, and historical and forecasted market size from 2020 to 2034 across the United States, EU4, the United Kingdom, and Japan.
Discover which open-angle glaucoma medications are expected to grab the market share @ https://www.delveinsight.com/report-store/open-angle-glaucoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Open-Angle Glaucoma Market Overview
The total open-angle glaucoma treatment market is expected to experience positive growth through 2034 across the major markets. Among these regions, the United States represents the largest market, followed by the EU4 countries, the UK, and Japan.
Approximately 80% of glaucoma cases in the United States are classified as open-angle glaucoma, making it the most common form of glaucoma in the country. The increasing prevalence of the disease, particularly among older adults, creates sustained demand for diagnosis, monitoring, pharmaceutical treatment, and surgical interventions.
Several companies are actively advancing therapies for open-angle glaucoma, including Omikron Italia, PolyActiva Pty, AbbVie, Perfuse Therapeutics, and Amydis. Pipeline candidates such as Citicolinem, PA5108, AGN-193408 SR, PER-001, and AMDX-2011P could introduce additional treatment options and potentially reshape the competitive landscape.
Aging Population and Disease Prevalence Support Market Growth
Age remains one of the strongest risk factors associated with open-angle glaucoma. As the global population of older adults expands, the number of individuals requiring long-term glaucoma monitoring and treatment is also expected to increase.
In the United States, at least 2.7 million people aged 40 years and older have been diagnosed with glaucoma, highlighting the considerable public health burden associated with the disease. Because glaucoma is chronic and progressive, patients may require prolonged treatment, creating recurring demand for pharmaceutical and procedural interventions.
Improved Screening Expands the Diagnosed Patient Pool
Greater awareness of glaucoma and advancements in screening technologies are also supporting market development. Wider adoption of optical coherence tomography, tele-ophthalmology, routine eye examinations, and other diagnostic approaches can facilitate earlier detection.
Earlier identification can increase the duration over which patients receive treatment and monitoring. As screening programs become more accessible, the diagnosed and treated patient population may continue to expand, strengthening opportunities across the open-angle glaucoma market.
Evolving Drug Classes and Treatment Approaches
Intraocular pressure reduction remains the central objective of open-angle glaucoma treatment. Established therapies include FP receptor agonists such as ZIOPTAN and XALATAN, beta-blockers such as timolol, alpha agonists such as brimonidine, and carbonic anhydrase inhibitors such as dorzolamide.
Newer therapies are introducing alternative mechanisms of action. OMLONTI, an EP2 receptor agonist, and RIPASUDIL, a Rho kinase inhibitor, provide additional approaches for improving aqueous humor outflow. Citicoline is another emerging option that has been investigated for mechanisms beyond conventional IOP reduction, including effects associated with glutathione stimulation.
Long-acting treatment options are also gaining attention. DURYSTA, a bimatoprost intracameral implant, was developed to provide sustained IOP control while potentially reducing dependence on daily eye drops.
Learn more about the open-angle glaucoma treatment options @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
MIGS Strengthens the Procedural Treatment Landscape
Minimally invasive glaucoma surgery is becoming an increasingly important component of the treatment landscape. Devices such as iStent, Hydrus Microstent, and Xen Gel Stent provide procedural options for patients requiring additional intervention.
MIGS approaches are designed to offer less invasive alternatives to traditional filtering procedures and may provide benefits related to safety, recovery, and treatment integration. Continued adoption of these technologies could contribute to the broader evolution of glaucoma management.
Pipeline Therapies Could Reshape Competition
The competitive landscape is becoming increasingly dynamic as multiple companies advance novel open-angle glaucoma candidates.
Omikron Italia's Citicoline is being evaluated in Phase II clinical development. Its proposed multifaceted activity includes preservation of cardiolipin and sphingomyelin, restoration of phosphatidylcholine, stimulation of glutathione production, reduction of glutamate levels, and support for mitochondrial function.
PolyActiva's PA5108 Ocular Implant uses its proprietary Prezia Sustained Drug Delivery Technology to deliver latanoprost free acid at a controlled daily dose. The implant is designed to provide zero-order drug release and undergo rapid, complete, and non-toxic biodegradation after treatment completion. PA5108 is currently being evaluated in Phase II clinical trials for primary open-angle glaucoma.
In December 2024, PolyActiva reported positive Phase II findings for PA5108, with the study meeting its primary efficacy and safety endpoints and demonstrating meaningful IOP reductions over 26 weeks.
The anticipated introduction of these therapies could create new treatment paradigms, increase patient choice, and intensify competition across the open-angle glaucoma market.
To know more about new treatment for open-angle glaucoma, visit @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Recent Developments in Open-Angle Glaucoma
In June 2025, Qlaris Bio presented new data for its investigational lead candidate QLS-111 at the 2025 World Glaucoma Congress. The presentation included findings from the Phase II Osprey studies evaluating the compound in patients with primary open-angle glaucoma and ocular hypertension.
Understanding Open-Angle Glaucoma
Open-angle glaucoma is a chronic and progressive optic neuropathy characterized by an open anterior chamber angle, optic nerve damage, retinal nerve fiber layer thinning, and gradual peripheral vision loss. In advanced disease, central vision can also become affected, potentially resulting in blindness.
Elevated intraocular pressure is an important risk factor and remains the primary therapeutic target, although glaucoma can develop even when IOP is not substantially elevated. The condition commonly affects both eyes, although severity may differ between them. Many patients remain asymptomatic during the early stages, emphasizing the importance of regular screening and timely diagnosis.
Download the report to understand which factors are driving open-angle glaucoma epidemiology trends @ https://www.delveinsight.com/report-store/open-angle-glaucoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Open-Angle Glaucoma Epidemiology Outlook
DelveInsight's open-angle glaucoma market forecast incorporates patient-based epidemiological analysis across the United States, EU4, the UK, and Japan. The assessment examines historical and projected patient trends and evaluates factors influencing disease prevalence and diagnosis.
The epidemiology analysis for 2020–2034 includes total prevalent cases, gender-specific cases, age-specific cases, and type-specific cases of open-angle glaucoma. These insights can help stakeholders understand changing patient demographics and identify opportunities across the evolving treatment landscape.
